Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis

Evidence and opinions

Ieva Ruza, Sasan Mirfakhraee, Eric Orwoll, Ugis Gruntmanis

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Osteoporosis frequently remains underrecognized and undertreated in men. Most osteoporosis-related fractures could be prevented if men at risk would be diagnosed, treated, and remained compliant with therapy. Bisphosphonates, the mainstay of osteoporosis treatment, are potent antiresorptive agents that inhibit osteoclast activity, suppress in vivo markers of bone turnover, increase bone mineral density, decrease fractures, and likely improve survival in men with osteoporosis. The focus of the article is on intravenous zoledronic acid, which may be a preferable alternative to oral bisphosphonate therapy in patients with cognitive dysfunction, the inability to sit upright, polypharmacy, significant gastrointestinal pathology or suspected medication noncompliance. Zoledronic acid is approved in the United States (US) and European Union (EU) as an annual 5 mg intravenous infusion to treat osteoporosis in men. The zoledronic acid 4 mg intravenous dose has been studied in the prevention of bone loss associated with androgen deprivation therapy. This article reviews the evidence for zoledronic acid, currently the most potent bisphosphonate available for clinical use, and its therapeutic effects in the treatment of men with osteoporosis.

Original languageEnglish (US)
Pages (from-to)182-198
Number of pages17
JournalTherapeutic Advances in Musculoskeletal Disease
Volume5
Issue number4
DOIs
StatePublished - Nov 2013

Fingerprint

zoledronic acid
Osteoporosis
Diphosphonates
Therapeutics
Bone Density Conservation Agents
Polypharmacy
Medication Adherence
Bone Remodeling
Therapeutic Uses
Osteoclasts
European Union
Intravenous Infusions
Bone Density
Androgens

Keywords

  • bisphosphonates
  • bone mineral density
  • fracture
  • men
  • osteoporosis
  • zoledronic acid

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine

Cite this

Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis : Evidence and opinions. / Ruza, Ieva; Mirfakhraee, Sasan; Orwoll, Eric; Gruntmanis, Ugis.

In: Therapeutic Advances in Musculoskeletal Disease, Vol. 5, No. 4, 11.2013, p. 182-198.

Research output: Contribution to journalArticle

@article{9ca8a8294de04a80b66a647ff6427339,
title = "Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: Evidence and opinions",
abstract = "Osteoporosis frequently remains underrecognized and undertreated in men. Most osteoporosis-related fractures could be prevented if men at risk would be diagnosed, treated, and remained compliant with therapy. Bisphosphonates, the mainstay of osteoporosis treatment, are potent antiresorptive agents that inhibit osteoclast activity, suppress in vivo markers of bone turnover, increase bone mineral density, decrease fractures, and likely improve survival in men with osteoporosis. The focus of the article is on intravenous zoledronic acid, which may be a preferable alternative to oral bisphosphonate therapy in patients with cognitive dysfunction, the inability to sit upright, polypharmacy, significant gastrointestinal pathology or suspected medication noncompliance. Zoledronic acid is approved in the United States (US) and European Union (EU) as an annual 5 mg intravenous infusion to treat osteoporosis in men. The zoledronic acid 4 mg intravenous dose has been studied in the prevention of bone loss associated with androgen deprivation therapy. This article reviews the evidence for zoledronic acid, currently the most potent bisphosphonate available for clinical use, and its therapeutic effects in the treatment of men with osteoporosis.",
keywords = "bisphosphonates, bone mineral density, fracture, men, osteoporosis, zoledronic acid",
author = "Ieva Ruza and Sasan Mirfakhraee and Eric Orwoll and Ugis Gruntmanis",
year = "2013",
month = "11",
doi = "10.1177/1759720X13485829",
language = "English (US)",
volume = "5",
pages = "182--198",
journal = "Therapeutic Advances in Musculoskeletal Disease",
issn = "1759-720X",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis

T2 - Evidence and opinions

AU - Ruza, Ieva

AU - Mirfakhraee, Sasan

AU - Orwoll, Eric

AU - Gruntmanis, Ugis

PY - 2013/11

Y1 - 2013/11

N2 - Osteoporosis frequently remains underrecognized and undertreated in men. Most osteoporosis-related fractures could be prevented if men at risk would be diagnosed, treated, and remained compliant with therapy. Bisphosphonates, the mainstay of osteoporosis treatment, are potent antiresorptive agents that inhibit osteoclast activity, suppress in vivo markers of bone turnover, increase bone mineral density, decrease fractures, and likely improve survival in men with osteoporosis. The focus of the article is on intravenous zoledronic acid, which may be a preferable alternative to oral bisphosphonate therapy in patients with cognitive dysfunction, the inability to sit upright, polypharmacy, significant gastrointestinal pathology or suspected medication noncompliance. Zoledronic acid is approved in the United States (US) and European Union (EU) as an annual 5 mg intravenous infusion to treat osteoporosis in men. The zoledronic acid 4 mg intravenous dose has been studied in the prevention of bone loss associated with androgen deprivation therapy. This article reviews the evidence for zoledronic acid, currently the most potent bisphosphonate available for clinical use, and its therapeutic effects in the treatment of men with osteoporosis.

AB - Osteoporosis frequently remains underrecognized and undertreated in men. Most osteoporosis-related fractures could be prevented if men at risk would be diagnosed, treated, and remained compliant with therapy. Bisphosphonates, the mainstay of osteoporosis treatment, are potent antiresorptive agents that inhibit osteoclast activity, suppress in vivo markers of bone turnover, increase bone mineral density, decrease fractures, and likely improve survival in men with osteoporosis. The focus of the article is on intravenous zoledronic acid, which may be a preferable alternative to oral bisphosphonate therapy in patients with cognitive dysfunction, the inability to sit upright, polypharmacy, significant gastrointestinal pathology or suspected medication noncompliance. Zoledronic acid is approved in the United States (US) and European Union (EU) as an annual 5 mg intravenous infusion to treat osteoporosis in men. The zoledronic acid 4 mg intravenous dose has been studied in the prevention of bone loss associated with androgen deprivation therapy. This article reviews the evidence for zoledronic acid, currently the most potent bisphosphonate available for clinical use, and its therapeutic effects in the treatment of men with osteoporosis.

KW - bisphosphonates

KW - bone mineral density

KW - fracture

KW - men

KW - osteoporosis

KW - zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=84887426739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887426739&partnerID=8YFLogxK

U2 - 10.1177/1759720X13485829

DO - 10.1177/1759720X13485829

M3 - Article

VL - 5

SP - 182

EP - 198

JO - Therapeutic Advances in Musculoskeletal Disease

JF - Therapeutic Advances in Musculoskeletal Disease

SN - 1759-720X

IS - 4

ER -